The humoral response of 39 meningioma patients to possible tumourassociated antigens was studied by means of an antibody dependent cell mediated cytotoxicity test (ADCC). Five patients were found to have cytotoxic antibodies against 1 to 10 meningioma cell lines. However, three of these were also cytotoxic against malignant glioma cell lines but not against other unrelated tumours. These results suggest the existence of surface antigens common to meningiomas and gliomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01400942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Memory responses to ovalbumin-immunization in Mojave desert tortoises.
Dev Comp Immunol
January 2025
Biology Department, University of Colorado - Pueblo, 2200 Bonforte Ave., Pueblo, CO 81001.
We immunized three groups of Mojave desert tortoises (Gopherus agassizii): a group immunized twice, a group immunized once, and a group sham-immunized. We used the antigen, ovalbumin (OVA), with Freund's adjuvant to elicit antibody responses similar to those induced by extracellular bacteria. All tortoises have relatively high levels of B1 lymphocytes and natural antibodies (NAbs), and the goal of this study was to quantify B2 lymphocyte activity (antibody production and potential proliferation) that occurs in primary and secondary immunizations against this constitutive, first line of humoral defense.
View Article and Find Full Text PDFLong-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses.
J Infect Public Health
January 2025
Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran. Electronic address:
Background: Given the limited available data about to the number of vaccine doses administered over an extended time in Iran, the immune status of vaccinated individuals and any potential disparities in this regard among those who received different numbers of vaccine doses remain unknown. Therefore, this study aimed to assess humoral immunity of individuals who received different doses of the COVID-19 vaccines in Iran.
Methods: This study was conducted from February, 2022 to December 2023 including 605 vaccinated subjects.
Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens.
J Nanobiotechnology
January 2025
College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China.
Background: The rapid mutation of avian influenza virus (AIV) poses a significant threat to both the poultry industry and public health. Herein, we have successfully developed an mRNA-LNPs candidate vaccine for H5 subtype highly pathogenic avian influenza and evaluated its immunogenicity and protective efficacy.
Results: In experiments on BALB/c mice, the vaccine candidate elicited strong humoral and a certain cellular immune responses and protected mice from the heterologous AIV challenge.
Antibody response to Plasmodium vivax in the context of Epstein-Barr virus (EBV) co-infection: A 14-year follow-up study in the Amazon rainforest.
PLoS One
January 2025
Instituto René Rachou, Fiocruz Minas, Fundação Oswaldo Cruz (Fiocruz), Belo Horizonte, Minas Gerais, Brazil.
Background: To develop an effective vaccine against Plasmodium vivax, the most widely dispersed human malaria parasite, it is critical to understand how coinfections with other pathogens could impact malaria-specific immune response. A recent conceptual study proposed that Epstein-Barr virus (EBV), a highly prevalent human herpesvirus that establishes lifelong persistent infection, may influence P. vivax antibody responses.
View Article and Find Full Text PDFBiogenic silver nanoparticle as an adjuvant in an S1 subunit recombinant vaccine.
Braz J Microbiol
January 2025
Center of Technological Development, Biotechnology, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.
Adjuvants are crucial for maintaining specific, protective, and long-lasting immunity. Here, we aimed to evaluate the antigenic and immunogenic activity of a recombinant form of the S1 domain of the Spike protein, associated with biogenic silver nanoparticles (bio-AgNP) and Alhydrogel as an alternative and conventional adjuvant, respectively, for a SARS-CoV-2 subunit vaccine. We produced and evaluated the antigenicity of the recombinant S1 (rS1) protein by testing its recognition by antibodies present in SARS-CoV-2 positive human serum.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!